The FDA clearance now allows physicians and nurse practitioners to gain authorization from insurance providers to treat adolescent patients. The Food and Drug Administration (FDA) has cleared ...
New Class of Navigated TMS Delivers Customized, Repeatable Treatments Improving Patient Care and Clinical Efficiencies MINNEAPOLIS & CARMARTHENSHIRE, Wales--(BUSINESS WIRE)--Magstim, the global leader ...
The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive ...
The FDA has granted Magstim Co. Ltd. 510(k) clearance for its transcranial magnetic stimulation (TMS) platform Horizon 3.0. TMS is a series of repetitive, focused magnetic pulses, used to stimulate ...
MINNEAPOLIS and CARMARTHENSHIRE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded FDA clearance ...
Magstim Inc. received U.S. FDA clearance for use of its Horizon 3.0 and E-z Cool Coil to treat adult patients diagnosed with both obsessive compulsive disorder (OCD) and major depressive disorder (MDD ...
MINNEAPOLIS, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Magstim, a global leader in neuroscience research and Transcranial Magnetic Stimulation (TMS) solutions for mental health, announced today that the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results